InterveXion Therapeutics Press Releases

• Published on July 5, 2022 - 13:15 GMT

  InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in Methamphetamine Use Disorder

  - First clinical trial of an anti-METH antibody in patients seeking treatment for methamphetamine use disorder LITTLE ROCK, ARKANSAS, USA, July 5, 2022 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on April 4, 2022 - 13:30 GMT

  InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming 'College on Problems in Drug Dependence' Meeting

  STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti-METH antibody LITTLE ROCK, ARKANSAS, USA, April 4, 2022 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company, today announced that it …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on October 4, 2021 - 12:49 GMT

  InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder

  Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on September 20, 2021 - 12:47 GMT

  InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose

  First clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, AR, USA, September 20, 2021 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of …

  Distribution channels: Emergency Services, Healthcare & Pharmaceuticals Industry ...
• Published on April 19, 2021 - 12:30 GMT

  InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder

  IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on October 5, 2020 - 12:30 GMT

  InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose

  "Meth-OD" trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on May 4, 2020 - 12:00 GMT

  InterveXion Awarded Federal Grant to Fund Ongoing Development of IXT-m200 for Methamphetamine Use Disorder

  Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation LITTLE ROCK, ARKANSAS, USA, May 4, 2020 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on August 12, 2019 - 12:00 GMT

  InterveXion Therapeutics Receives Japanese Patent for IXT-m200 (Anti-Methamphetamine Antibody)

  LITTLE ROCK, ARKANSAS, USA, August 12, 2019 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on July 29, 2019 - 09:00 GMT

  InterveXion Announces Positive Results from Pre-Specified Interim Review of Phase 2 STAMPOUT Study

  IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage …

  Distribution channels: Business & Economy, Companies ...
• Published on May 20, 2019 - 14:59 GMT

  InterveXion Names Industry Veteran Keith W. Ward as President and Chief Executive Officer

  LITTLE ROCK, AR, UNITED STATES, May 20, 2019 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced that its Board of …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on May 13, 2019 - 18:50 GMT

  InterveXion Announces Expansion of Executive Leadership Team

  LITTLE ROCK, AR, UNITED STATES, May 13, 2019 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on May 23, 2018 - 16:58 GMT

  InterveXion to Present IXT-m200 Program and Phase 2 STAMPOUT Design at College on Problems in Drug Dependence Meeting

  STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users LITTLE ROCK, AR, USA, May 23, 2018 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a private clinical-stage …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on May 10, 2018 - 01:57 GMT

  InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD

  STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users LITTLE ROCK, ARKANSAS, USA, May 9, 2018 /⁨EINPresswire.com⁩/ -- InterveXion announces the enrollment of the first patient in …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on January 4, 2018 - 17:45 GMT

  InterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics

  LITTLE ROCK, AR, USA, January 4, 2018 /EINPresswire.com/ -- InterveXion Therapeutics, a biopharmaceutical company focused on developing novel therapies to treat drug addiction, and Ascent Therapeutics, a company dedicated to advancing Asian development of …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on October 10, 2017 - 14:31 GMT

  InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication

  LITTLE ROCK, AR, USA, October 10, 2017 /EINPresswire.com/ -- InterveXion Therapeutics has received a federal grant to fund a second clinical study of IXT-m200, a monoclonal antibody designed to treat methamphetamine abuse. The clinical trial, called …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...